All patients also received appropriate therapy for heart failure with beta-blockers, angiotensin receptor–neprilysin inhibitors/ACE inhibitors/angiotensin receptor blockers, mineralocorticoid receptor antagonists and diuretics according to current ESC Guidelines [16]. Here, NR3C2 is linked to heart failure.